Side-by-side · Research reference

TB-500vsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED8/46 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

TB-500

Vesugen

Primary target

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

Endogenous protein at baseline; supplementation amplifies

Not applicable — does not operate via hormone axis

Origin

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

TB-500

Vesugen

Standard dose

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

—

Frequency

2× per week (loading); then 1× per week (maintenance)

Not specified in available literature

Lower / starter dose

1 mg per injection

—

Evidence basis

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Duration

4–8 weeks loading; longer maintenance for chronic injury

Case series report treatment courses in elderly arterial insufficiency

Reconstitution

Bacteriostatic water, 1–2 mL per 5 mg vial

—

Timing

Evening or pre-rest preferred (anecdotal)

—

Half-life

~2 hours (estimated; tissue uptake longer)

Not reported

Tripeptides typically cleared rapidly.

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

04Side Effects & Safety

Parameter

TB-500

Vesugen

Injection site reaction

Mild erythema, transient pain

—

GI symptoms

Rare nausea (anecdotal)

—

Cancer risk

Theoretical via angiogenesis pathway

—

Lethargy / fatigue

Reported anecdotally during loading phase

—

Antibody formation

No data (no long-term human trials)

—

Pregnancy / OB

Avoid

—

Long-term safety

Unknown beyond Phase 2

Unknown — no long-term RCT data

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Vesugen

—

Relative Contraindications

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

TB-500

Vesugen

1. Reconstitution

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Injection site

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Timing

Evening or pre-sleep is most common anecdotal timing.

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

5. Needle

27–31G, 4–8 mm insulin syringe.

—

06Stack Synergy

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)